Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults

Journal of Medical Virology

Volumn 69, Issue 4, 2003, Pages 560-567

  Ben Yehuda, Arie ^a   Joseph, Aviva ^a   Zeira, Evelyne ^a   Even Chen, Simcha ^a   Louria Hayon, Igal ^a   Babai, Ilan ^a   Zakay Rones, Zichria ^a   Greenbaum, Evgenia ^a   Barenholz, Yechezkel ^a   Kedar, Eli ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Influenza; INFLUSOME VAC; Young adults

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; INFLUSOME VAC; RECOMBINANT INTERLEUKIN 2;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; ERYTHEMA; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MORBIDITY; MORTALITY; MOUSE; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; NORMAL HUMAN; NOSE CONGESTION; PAIN; PRURITUS; SEROCONVERSION; SORE THROAT; VERTIGO;

ADOLESCENT; ADULT; ANIMALS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERLEUKIN-2; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEURAMINIDASE; RECOMBINANT PROTEINS;

EID: 0037399598     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10345     Document Type: Article

References (37)

1. Advisory Committee on Immunization Practices. 2000. Prevention and control of influenza: recommendations of the MMWR Morb Mortal Wkly Rep 49(RR-3):1-38.
2. Alving CR. 1997. Liposomes as adjuvants for vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New generation vaccines. 2nd ed. New York: Marcel Dekker. p 207-213.
3. Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. 1973. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull WHO 48:199-202.
4. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. 1999a. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine 17:1223-1238.
5. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. 1999b. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine 17:1239-1250.
6. Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, Rochman M, Kedar E. 2001. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine 20:505-515.
7. Barenholz Y, Amselem S. 1993. Liposome preparation and related techniques. In: Gregoriadis G, editor. Liposome technology. Vol. 1. 2nd ed. Boca Raton, FL: CRC Press. p 527-616.
8. Barker WH, Mullooly JP. 1980. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 112:798-811.
9. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. 1998. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 16:1722-1731.
10. Bishara A, Kedar E, Leshem B, Rosenkovitch E, Brautbar C. 1991. A short human and mouse MLR assay utilizing lymphokine (IL-2, IL-3) secretion as an early activation event. Transplantation 51:1104-1109.
11. Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S. 1999. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 80:2559-2564.
12. Couch RB, Kasel JA. 1983. Immunity to influenza in man. Annu Rev Microbiol 37:529-549.
13. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A. 1999. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF 59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17: 99-104.
14. Glück R. 1992. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 10:915-919.
15. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. 1994. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344:160-163.
16. Gregoriadis G. 1994. Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods 4:210-216.
17. Hilbert AK, Fritzsche U, Kissel T. 1999. Biodegradable microspheres containing influenza A vaccine: immune response in mice. Vaccine 17:1065-1073.
18. Johansson BE, Kilbourne ED. 1991. Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine. Vaccine 9:330-333.
19. Kedar E, Barenholz Y. 1998. Delivery of cytokines by liposomes: a means of improving their immunomodulatory and anti-tumor activity. In: Chouaib S, editor. The biotherapy of cancers: from immunotherapy to gene therapy. Paris: INSERM. p 333-362.
20. Kedar E, Rutkowski Y, Braun E, Emanuel N, Barenholz Y. 1994. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J Immunother 16:47-59.
21. Kilbourne ED, Arden NH. 1999. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WA Saunders. p 531-551.
22. Kilbourne ED, Johansson BE, Grajower B. 1990. Independent and disparate evolution in nature of influenza A virus haemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci USA 87:786-790.
23. Kilbourne ED, Couch RB, Kasel JA, Keitel WA, Cate TR, Quarles JH, Grajower B, Pokorny BA, Johansson BE. 1995. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13:1799-1803.
24. Kunzel W, Glathe H, Engelmann H, Van Hoecke C. 1996. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 14:1108-1110.
25. Lachman LB, Shih LC, Rao XM, Hu X, Bucana CD, Ullrich SE, Cleland JL. 1995. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses 11:921-932.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
27. Luther P, Klett GE, Weber S, Pechmann H, Bergmann KC. 1983. The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. J Biol Stand 11:115-121.
28. Mbawuike IN, Wyde PR, Anderson PM. 1990. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 8:347-352.
29. Nichol KL, Margolis KL, Wuorenma J, von Sternberg T. 1994. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331:778-784.
30. Nichol KL, Wuorenma J, von Sternberg T. 1998. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158:1769-1776.
31. Peterson GL. 1983. Determination of total protein. Methods Enzymol 91:95-119.
32. Powers DC. 1997. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mech Ageing Dev 93:179-188.
33. Provinciali M, Di Stefano G, Colombo M, Della Croce F, Gandolfi MC, Daghetta L, Anichini M, Della Bitta R, Fabris N. 1994. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech Ageing Dev 77:75-82.
34. Rimmelzwaan GF, Claas EC, van Amerongen G, de Jong JC, Osterhaus AD. 1999. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 17:1355-1358.
35. Sever J. 1962. Application of microtechnique to viral serologic investigation. J Immunol 88:321-325.
36. van Slooten ML, Hayon I, Babai I, Zakay-Rones Z, Wagner E, Storm G, Kedar E. 2001. Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines. Biochim Biophys Acta 1531:99-110.
37. Webster RG, Reay PA, Laver WG. 1988. Protection against lethal influenza with neuraminidase. Virology 164:230-237.